Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RLMD Relmada Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RLMD
Price (delayed)
$0.61
Market cap
$20.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.51
Enterprise value
$19.1M
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed
Highlights
The EPS has grown by 20% YoY and by 5% from the previous quarter
Relmada Therapeutics's net income has increased by 20% YoY and by 5% QoQ
The quick ratio has contracted by 24% YoY but it has grown by 19% from the previous quarter
RLMD's equity has plunged by 69% YoY and by 37% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.relmada.com
Key stats
What are the main financial stats of RLMD
Market
Valuations
Earnings
Shares outstanding
33.19M
Market cap
$20.25M
Enterprise value
$19.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$79.12M
Net income
-$75.71M
EBIT
-$75.71M
EBITDA
-$75.71M
Free cash flow
-$56.79M
Per share
Balance sheet
Liquidity
EPS
-$2.51
EPS diluted
-$2.51
Free cash flow per share
-$1.87
Book value per share
$0.68
Revenue per share
$0
TBVPS
$0.91
Total assets
$27.68M
Total liabilities
$5.24M
Debt
$0
Equity
$22.44M
Working capital
$22.43M
Debt to equity
0
Current ratio
5.29
Quick ratio
5.17
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-151.2%
Return on equity
-181.3%
Return on invested capital
-191%
Return on capital employed
-337.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLMD stock price
How has the Relmada Therapeutics stock price performed over time
Intraday
-8.97%
1 week
-3.17%
1 month
-20.42%
1 year
-86.01%
YTD
17.31%
QTD
1.62%
Financial performance
How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$79.12M
Net income
-$75.71M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's operating income has increased by 20% YoY and by 6% from the previous quarter
Relmada Therapeutics's net income has increased by 20% YoY and by 5% QoQ
Price vs fundamentals
How does RLMD's price correlate with its fundamentals
Growth
What is Relmada Therapeutics's growth rate over time
Valuation
What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
0.9
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 20% YoY and by 5% from the previous quarter
RLMD's equity has plunged by 69% YoY and by 37% from the previous quarter
The P/B is 68% less than the 5-year quarterly average of 2.8 and 18% less than the last 4 quarters average of 1.1
Efficiency
How efficient is Relmada Therapeutics business performance
Relmada Therapeutics's return on equity has shrunk by 78% YoY and by 23% QoQ
RLMD's return on invested capital has dropped by 74% year-on-year and by 24% since the previous quarter
The ROA has dropped by 66% year-on-year and by 21% since the previous quarter
Dividends
What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLMD.
Financial health
How did Relmada Therapeutics financials performed over time
Relmada Therapeutics's total assets has shrunk by 67% YoY and by 40% QoQ
RLMD's total liabilities has shrunk by 58% YoY and by 49% QoQ
RLMD's debt is 100% smaller than its equity
RLMD's equity has plunged by 69% YoY and by 37% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.